+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bleeding Disorders Therapeutics Market by Type and Geography - Forecast and Analysis 2020-2024 - Product Image

Bleeding Disorders Therapeutics Market by Type and Geography - Forecast and Analysis 2020-2024

  • ID: 4855488
  • Report
  • November 2019
  • Region: Global
  • 170 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Baxter International Inc.
  • Bayer AG
  • CSL Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • Novo Nordisk AS
  • MORE
Global Bleeding Disorders Therapeutics Market: About this market
The bleeding disorders therapeutics market analysis considers sales from types of bleeding disorders therapeutics such as Hemophilia A, Hemophilia B, Von Willebrand disease, and other disorders. Our report also provides a detailed analysis of the market in Asia, Europe, North America, and ROW. In 2019, the Hemophilia A segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing demand for therapeutics without human or animal proteins will play a significant role in the Hemophilia A segment to maintain its market position. Also, our global bleeding disorders therapeutics market report looks at factors such as rising initiatives to increase awareness, recent approvals, and regulatory incentives. However, high costs of treatment, difficulties associated with early treatment, and challenges related to diagnosis and management of bleeding disorders may hamper the growth of the bleeding disorders therapeutics industry over the forecast period.

Global Bleeding Disorders Therapeutics Market: Overview

Rising initiatives to increase awareness
The awareness campaigns aids in the early detection of bleeding disorders, aiding patients to start therapy in the initial stages of the disorder. Organizations such as the National Hemophilia Foundation, von Willebrand Education Network, and World Federation of Hemophilia support and are focused on raising both awareness and research funds for bleeding disorders. This increasing awareness will lead to the expansion of the global bleeding disorders therapeutics market at a CAGR of almost 7% during the forecast period.

The emergence of gene therapy
Gene therapy is one of the most advanced and extensively researched treatment methods to treat hemophilia and von Willebrand disease. This therapy delivers stable insertion and expression of a gene, whose absence is responsible for a particular bleeding disorder. Therefore, the emergence and approval of gene therapies are expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of a few significant players, the global bleeding disorders therapeutics market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading bleeding disorders therapeutics manufacturers, that include Baxter International Inc., Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd., Grifols SA, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.

Also, the bleeding disorders therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Baxter International Inc.
  • Bayer AG
  • CSL Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • Novo Nordisk AS
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Hemophilia A - Market size and forecast 2019-2024
  • Hemophilia B - Market size and forecast 2019-2024
  • Von Willebrand disease - Market size and forecast 2019-2024
  • Other disorders - Market size and forecast 2019-2024
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • R&D of novel therapies
  • Emergence of gene therapy
  • Advent of bispecific antibodies
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Baxter International Inc.
  • Bayer AG
  • CSL Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • Novo Nordisk AS
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Late-stage pipeline
Exhibit 19: Type - Market share 2019-2024 (%)
Exhibit 20: Comparison by type
Exhibit 21: Hemophilia A - Market size and forecast 2019-2024 ($ millions)
Exhibit 22: Hemophilia A - Year-over-year growth 2020-2024 (%)
Exhibit 23: Hemophilia B - Market size and forecast 2019-2024 ($ millions)
Exhibit 24: Hemophilia B - Year-over-year growth 2020-2024 (%)
Exhibit 25: Von Willebrand disease - Market size and forecast 2019-2024 ($ millions)
Exhibit 26: Von Willebrand disease - Year-over-year growth 2020-2024 (%)
Exhibit 27: Other disorders - Market size and forecast 2019-2024 ($ millions)
Exhibit 28: Other disorders - Year-over-year growth 2020-2024 (%)
Exhibit 29: Market opportunity by type
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2019-2024 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 34: North America - Year-over-year growth 2020-2024 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Baxter International Inc. - Vendor overview
Exhibit 54: Baxter International Inc. - Business segments
Exhibit 55: Baxter International Inc. - Organizational developments
Exhibit 56: Baxter International Inc. - Geographic focus
Exhibit 57: Baxter International Inc. - Segment focus
Exhibit 58: Baxter International Inc. - Key offerings
Exhibit 59: Baxter International Inc. - Key customers
Exhibit 60: Bayer AG - Vendor overview
Exhibit 61: Bayer AG - Business segments
Exhibit 62: Bayer AG - Organizational developments
Exhibit 63: Bayer AG - Geographic focus
Exhibit 64: Bayer AG - Segment focus
Exhibit 65: Bayer AG - Key offerings
Exhibit 66: Bayer AG - Key customers
Exhibit 67: CSL Ltd. - Vendor overview
Exhibit 68: CSL Ltd. - Business segments
Exhibit 69: CSL Ltd. - Organizational developments
Exhibit 70: CSL Ltd. - Geographic focus
Exhibit 71: CSL Ltd. - Segment focus
Exhibit 72: CSL Ltd. - Key offerings
Exhibit 73: CSL Ltd. - Key customers
Exhibit 74: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 75: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 76: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 77: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 78: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 79: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 80: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 81: Grifols SA - Vendor overview
Exhibit 82: Grifols SA - Business segments
Exhibit 83: Grifols SA - Organizational developments
Exhibit 84: Grifols SA - Geographic focus
Exhibit 85: Grifols SA - Segment focus
Exhibit 86: Grifols SA - Key offerings
Exhibit 87: Grifols SA - Key customers
Exhibit 88: Novo Nordisk AS - Vendor overview
Exhibit 89: Novo Nordisk AS - Business segments
Exhibit 90: Novo Nordisk AS - Organizational developments
Exhibit 91: Novo Nordisk AS - Geographic focus
Exhibit 92: Novo Nordisk AS - Segment focus
Exhibit 93: Novo Nordisk AS - Key offerings
Exhibit 94: Novo Nordisk AS - Key customers
Exhibit 95: Octapharma AG - Vendor overview
Exhibit 96: Octapharma AG - Organizational developments
Exhibit 97: Octapharma AG - Key offerings
Exhibit 98: Octapharma AG - Key customers
Exhibit 99: Pfizer Inc. - Vendor overview
Exhibit 100: Pfizer Inc. - Business segments
Exhibit 101: Pfizer Inc. - Organizational developments
Exhibit 102: Pfizer Inc. - Geographic focus
Exhibit 103: Pfizer Inc. - Segment focus
Exhibit 104: Pfizer Inc. - Key offerings
Exhibit 105: Pfizer Inc. - Key customers
Exhibit 106: Sanofi - Vendor overview
Exhibit 107: Sanofi - Business segments
Exhibit 108: Sanofi - Organizational developments
Exhibit 109: Sanofi - Geographic focus
Exhibit 110: Sanofi - Segment focus
Exhibit 111: Sanofi - Key offerings
Exhibit 112: Sanofi - Key customers
Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 116: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 117: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 118: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 119: Validation techniques employed for market sizing
Exhibit 120: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Baxter International Inc.
  • Bayer AG
  • CSL Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • Novo Nordisk AS
  • MORE
The following companies as the key players in the global bleeding disorders therapeutics market: Baxter International Inc., Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd., Grifols SA, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emergence of gene therapy.”

According to the report, one of the major drivers for this market is the rising initiatives to increase awareness

Further, the report states that one of the major factors hindering the growth of this market is the high costs of treatment

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Baxter International Inc.
  • Bayer AG
  • CSL Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Grifols SA
  • Novo Nordisk AS
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll